Tsinghua-backed Rokae is working on lightweight robots with a wide range of applications and has now raised $43.5m altogether.

GI Windows Medical plans to put the $16.4m from the Johnson & Johnson Innovation – JJDC-backed round into clinical validation of its anastomotic endoscopy device.

Eli Lilly and WuXi Biologics-backed biologics developer Inhibrx floated at the midpoint of its range having previously raised $135m in debt and equity financing.

Dizal, co-founded by AstraZeneca three years ago to develop therapies for a broad range of diseases, pulled in $100m through a round led by Lilly Asia Ventures.

Reliance Industries has paid $82.6m for a majority stake in NetMeds, an online pharmacy that had raised $99m from backers including Daun Penh Cambodia Group and Sistema.

Sequoia Capital China led a $72.3m round for the drug developer, which counts Xiamen Air and Pien Tze Huang-among its early investors.

Johnson & Johnson, Takeda, Novartis and Bukwang Pharmaceutical all backed the first round disclosed by oncology drug developer Immpact Bio USA.

Hillhouse Capital is set to supply more than $830m for JD.com's pharmaceutical and medical services spinoff, which raised about $1bn last year.

Collaboration partner Gilead Sciences provided $20m as the cancer therapy researcher extended its overall equity funding to $165m.

Portland State University spinout DesignMedix has shut down after its phase 1 trial for an antimalaria treatment caused side effects.